Identification

Name
Labetalol
Accession Number
DB00598  (APRD01062)
Type
Small Molecule
Groups
Approved
Description

Blocker of both alpha- and beta-adrenergic receptors that is used as an antihypertensive. [PubChem]

Structure
Thumb
Synonyms
  • 3-Carboxamido-4-hydroxy-alpha-((1-methyl-3-phenylpropylamino)methyl)benzyl alcohol
  • 5-(1-Hydroxy-2-(1-methyl-3-phenylpropylamino)ethyl)salicylamide
  • Labetalol
  • Labetalolum
  • Labetolol
Product Ingredients
IngredientUNIICASInChI Key
Labetalol Hydrochloride1GEV3BAW9J32780-64-6WQVZLXWQESQGIF-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Labetalol HydrochlorideTablet300 mg/1OralCounty Line Pharamceuticals2014-12-01Not applicableUs
Labetalol HydrochlorideTablet300 mg/1Oralbryant ranch prepack2014-12-01Not applicableUs
Labetalol HydrochlorideTablet, film coated200 mg/1OralAlvogen, Inc.2018-03-01Not applicableUs
Labetalol HydrochlorideTablet200 mg/1OralA S Medication Solutions2014-12-012017-06-20Us
Labetalol HydrochlorideTablet200 mg/1OralCounty Line Pharamceuticals2014-12-01Not applicableUs43199 0038 01 nlmimage10 5644ab15
Labetalol HydrochlorideTablet100 mg/1OralNucare Pharmaceuticals, Inc.2014-12-01Not applicableUs
Labetalol HydrochlorideTablet, film coated100 mg/1OralAlvogen, Inc.2018-03-01Not applicableUs
Labetalol HydrochlorideTablet100 mg/1OralSt. Marys Medical Park Pharmacy2014-12-01Not applicableUs
Labetalol HydrochlorideTablet100 mg/1OralRemedy Repack2016-11-30Not applicableUs
Labetalol HydrochlorideTablet, film coated300 mg/1OralAlvogen, Inc.2018-03-01Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-labetalol TabletsTablet200 mgOralApotex Corporation2001-06-01Not applicableCanada
Apo-labetalol TabletsTablet100 mgOralApotex Corporation2001-03-16Not applicableCanada
LabetalolTablet, film coated300 mg/1OralSun Pharmaceutical Industries Limited1999-07-292018-05-11Us
LabetalolTablet, film coated200 mg/1OralMarlex Pharmaceuticals Inc2018-04-01Not applicableUs
LabetalolTablet, film coated200 mg/1OralSun Pharmaceutical Industries Limited1999-07-292018-05-11Us
LabetalolTablet, film coated100 mg/1OralMarlex Pharmaceuticals Inc2018-04-01Not applicableUs
LabetalolInjection, solution5 mg/mLIntravenousSagent Pharmaceuticals2010-02-172017-06-20Us
LabetalolTablet, film coated300 mg/1OralMarlex Pharmaceuticals Inc2018-04-01Not applicableUs
LabetalolTablet, film coated100 mg/1OralSun Pharmaceutical Industries Limited1999-07-292018-05-11Us
Labetalol HClTablet, film coated100 mg/1OralEon Labs, Inc.1998-08-04Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Labetalol HClLabetalol Hydrochloride (5 mg/mL)Injection, solutionIntravenousCantrell Drug Company2012-02-23Not applicableUs
International/Other Brands
Albetol (Leiras) / Latol (Standard) / Normadate (GlaxoSmithKline) / Normodyne (Schering)
Categories
UNII
R5H8897N95
CAS number
36894-69-6
Weight
Average: 328.4055
Monoisotopic: 328.178692644
Chemical Formula
C19H24N2O3
InChI Key
SGUAFYQXFOLMHL-UHFFFAOYSA-N
InChI
InChI=1S/C19H24N2O3/c1-13(7-8-14-5-3-2-4-6-14)21-12-18(23)15-9-10-17(22)16(11-15)19(20)24/h2-6,9-11,13,18,21-23H,7-8,12H2,1H3,(H2,20,24)
IUPAC Name
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide
SMILES
CC(CCC1=CC=CC=C1)NCC(O)C1=CC(C(N)=O)=C(O)C=C1

Pharmacology

Indication

For the management of hypertension (alone or in combination with other classes of antihypertensive agents), as well as chronic stable angina pectoris and sympathetic overactivity syndrome associated with severe tetanus. Labetalol is used parenterally for immediate reduction in blood pressure in severe hypertension or in hypertensive crises when considered an emergency, for the control of blood pressure in patients with pheochromocytoma and pregnant women with preeclampsia, and to produce controlled hypotension during anesthesia to reduce bleeding resulting from surgical procedures.

Associated Conditions
Pharmacodynamics

Labetalol is an selective alpha-1 and non-selective beta adrenergic blocker used to treat high blood pressure. It works by blocking these adrenergic receptors, which slows sinus heart rate, decreases peripheral vascular resistance, and decreases cardiac output. Labetalol has two asymmetric centers and therefore, exists as a molecular complex of two diastereoisomeric pairs. Dilevalol, the R,R' stereoisomer, makes up 25% of racemic labetalol.

Mechanism of action

Labetalol HCl combines both selective, competitive, alpha-1-adrenergic blocking and nonselective, competitive, beta-adrenergic blocking activity in a single substance. In man, the ratios of alpha- to beta- blockade have been estimated to be approximately 1:3 and 1:7 following oral and intravenous (IV) administration, respectively. The principal physiologic action of labetalol is to competitively block adrenergic stimulation of β-receptors within the myocardium (β1-receptors) and within bronchial and vascular smooth muscle (β2-receptors), and α1-receptors within vascular smooth muscle. This causes a decrease in systemic arterial blood pressure and systemic vascular resistance without a substantial reduction in resting heart rate, cardiac output, or stroke volume, apparently because of its combined α- and β-adrenergic blocking activity.

TargetActionsOrganism
ABeta-1 adrenergic receptor
antagonist
Human
ABeta-2 adrenergic receptor
antagonist
Human
AAlpha-1 adrenergic receptors
antagonist
Human
Absorption

Completely absorbed (100%) from the gastrointestinal tract with peak plasma levels occurring 1 to 2 hours after oral administration. The absolute bioavailability of labetalol is increased when administered with food.

Volume of distribution
Not Available
Protein binding

50%

Metabolism

Primarily hepatic, undergoes significant first pass metabolism

Route of elimination

These metabolites are present in plasma and are excreted in the urine, and via the bile, into the feces.

Half life

6-8 hours

Clearance
Not Available
Toxicity

LD50 = 66 mg/kg (Rat, IV). Side effects or adverse reactions include dizziness when standing up, very low blood pressure, severely slow heartbeat, weakness, diminished sexual function, fatigue

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Labetalol Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Labetalol.Experimental
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of adverse effects can be increased when Labetalol is combined with 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when Labetalol is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3-isobutyl-1-methyl-7H-xanthineThe risk or severity of adverse effects can be increased when Labetalol is combined with 3-isobutyl-1-methyl-7H-xanthine.Experimental
3,4-MethylenedioxyamphetamineThe risk or severity of adverse effects can be increased when Labetalol is combined with 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when Labetalol is combined with 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineThe therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Labetalol.Experimental, Illicit
6-O-benzylguanineThe risk or severity of adverse effects can be increased when Labetalol is combined with 6-O-benzylguanine.Investigational
7-DeazaguanineThe risk or severity of adverse effects can be increased when Labetalol is combined with 7-Deazaguanine.Experimental
7,9-DimethylguanineThe risk or severity of adverse effects can be increased when Labetalol is combined with 7,9-Dimethylguanine.Experimental
8-azaguanineThe risk or severity of adverse effects can be increased when Labetalol is combined with 8-azaguanine.Experimental
8-chlorotheophyllineThe risk or severity of adverse effects can be increased when Labetalol is combined with 8-chlorotheophylline.Approved
9-DeazaguanineThe risk or severity of adverse effects can be increased when Labetalol is combined with 9-Deazaguanine.Experimental
9-MethylguanineThe risk or severity of adverse effects can be increased when Labetalol is combined with 9-Methylguanine.Experimental
AbediterolThe therapeutic efficacy of Abediterol can be decreased when used in combination with Labetalol.Investigational
AbirateroneThe serum concentration of Labetalol can be increased when it is combined with Abiraterone.Approved
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Labetalol.Approved, Investigational
AceclofenacAceclofenac may decrease the antihypertensive activities of Labetalol.Approved, Investigational
AcefyllineThe risk or severity of adverse effects can be increased when Labetalol is combined with Acefylline.Experimental
AcemetacinAcemetacin may decrease the antihypertensive activities of Labetalol.Approved, Experimental, Investigational
AcepromazineLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.Approved, Vet Approved
AceprometazineThe serum concentration of Labetalol can be increased when it is combined with Aceprometazine.Approved
AcetohexamideLabetalol may increase the hypoglycemic activities of Acetohexamide.Approved, Investigational, Withdrawn
AcetophenazineThe serum concentration of Labetalol can be increased when it is combined with Acetophenazine.Approved
AcetylcholineThe risk or severity of adverse effects can be increased when Labetalol is combined with Acetylcholine.Approved
AcetyldigitoxinLabetalol may increase the bradycardic activities of Acetyldigitoxin.Approved
AcetyldigoxinLabetalol may increase the bradycardic activities of Acetyldigoxin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Labetalol.Approved, Vet Approved
AcyclovirThe risk or severity of adverse effects can be increased when Labetalol is combined with Acyclovir.Approved
AdrafinilThe therapeutic efficacy of Adrafinil can be decreased when used in combination with Labetalol.Withdrawn
AgmatineThe therapeutic efficacy of Agmatine can be decreased when used in combination with Labetalol.Experimental, Investigational
Agrostis gigantea pollenThe risk of a hypersensitivity reaction to Agrostis gigantea pollen is increased when it is combined with Labetalol.Approved
Agrostis stolonifera pollenThe risk of a hypersensitivity reaction to Agrostis stolonifera pollen is increased when it is combined with Labetalol.Approved
Ajulemic acidThe risk or severity of Tachycardia can be increased when Ajulemic acid is combined with Labetalol.Investigational
AlaproclateThe serum concentration of Labetalol can be increased when it is combined with Alaproclate.Experimental
AlclofenacAlclofenac may decrease the antihypertensive activities of Labetalol.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Labetalol.Approved
AlfentanilAlfentanil may increase the bradycardic activities of Labetalol.Approved, Illicit
AlimemazineThe serum concentration of Labetalol can be increased when it is combined with Alimemazine.Approved, Vet Approved
AliskirenLabetalol may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlminoprofenAlminoprofen may decrease the antihypertensive activities of Labetalol.Experimental
AlprenololAlprenolol may increase the orthostatic hypotensive activities of Labetalol.Approved, Withdrawn
AmbenoniumAmbenonium may increase the bradycardic activities of Labetalol.Approved
AmbrisentanLabetalol may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmibegronThe therapeutic efficacy of Amibegron can be decreased when used in combination with Labetalol.Investigational
AmifostineLabetalol may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Labetalol.Approved
AminophenazoneAminophenazone may decrease the antihypertensive activities of Labetalol.Approved, Withdrawn
AmiodaroneThe therapeutic efficacy of Labetalol can be increased when used in combination with Amiodarone.Approved, Investigational
AmitrazThe therapeutic efficacy of Amitraz can be decreased when used in combination with Labetalol.Vet Approved
AmitriptylineLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Amitriptyline.Approved
AmlodipineThe risk or severity of hypotension can be increased when Labetalol is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Labetalol.Approved, Illicit
AmodiaquineThe risk or severity of QTc prolongation can be decreased when Amodiaquine is combined with Labetalol.Approved, Investigational
AmoxapineLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Amoxapine.Approved
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Labetalol.Approved, Illicit, Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Labetalol.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Labetalol is combined with Amyl Nitrite.Approved
AnisodamineThe therapeutic efficacy of Anisodamine can be decreased when used in combination with Labetalol.Investigational
Anthoxanthum odoratum pollenThe risk of a hypersensitivity reaction to Anthoxanthum odoratum pollen is increased when it is combined with Labetalol.Approved
AntipyrineAntipyrine may decrease the antihypertensive activities of Labetalol.Approved, Investigational
AntrafenineAntrafenine may decrease the antihypertensive activities of Labetalol.Approved
ApomorphineThe therapeutic efficacy of Apomorphine can be decreased when used in combination with Labetalol.Approved, Investigational
ApraclonidineThe therapeutic efficacy of Apraclonidine can be decreased when used in combination with Labetalol.Approved
AranidipineThe risk or severity of hypotension can be increased when Labetalol is combined with Aranidipine.Approved, Investigational
ArbutamineThe therapeutic efficacy of Arbutamine can be decreased when used in combination with Labetalol.Approved
ArdeparinThe risk or severity of hyperkalemia can be increased when Ardeparin is combined with Labetalol.Approved, Investigational, Withdrawn
ArecolineThe risk or severity of adverse effects can be increased when Labetalol is combined with Arecoline.Experimental
ArformoterolThe therapeutic efficacy of Arformoterol can be decreased when used in combination with Labetalol.Approved, Investigational
ArotinololArotinolol may increase the orthostatic hypotensive activities of Labetalol.Investigational
Arrhenatherum elatius pollenThe risk of a hypersensitivity reaction to Arrhenatherum elatius pollen is increased when it is combined with Labetalol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Labetalol.Approved, Investigational
AsenapineLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Asenapine.Approved
AsunaprevirThe metabolism of Labetalol can be decreased when combined with Asunaprevir.Approved, Investigational, Withdrawn
AtenololAtenolol may increase the orthostatic hypotensive activities of Labetalol.Approved
AtomoxetineThe risk or severity of hypertension can be increased when Atomoxetine is combined with Labetalol.Approved
AvanafilAvanafil may increase the antihypertensive activities of Labetalol.Approved
AzapropazoneAzapropazone may decrease the antihypertensive activities of Labetalol.Withdrawn
AzathioprineThe risk or severity of adverse effects can be increased when Labetalol is combined with Azathioprine.Approved
AzelnidipineThe risk or severity of hypotension can be increased when Labetalol is combined with Azelnidipine.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Labetalol is combined with Azilsartan medoxomil.Approved, Investigational
BalsalazideBalsalazide may decrease the antihypertensive activities of Labetalol.Approved, Investigational
BambuterolThe therapeutic efficacy of Bambuterol can be decreased when used in combination with Labetalol.Approved, Investigational
BamifyllineThe risk or severity of adverse effects can be increased when Labetalol is combined with Bamifylline.Experimental
BarbexacloneBarbexaclone may increase the hypotensive activities of Labetalol.Experimental
BarbitalBarbital may increase the hypotensive activities of Labetalol.Illicit
BarnidipineLabetalol may increase the antihypertensive activities of Barnidipine.Approved
BefunololThe therapeutic efficacy of Befunolol can be decreased when used in combination with Labetalol.Experimental
BemiparinThe risk or severity of hyperkalemia can be increased when Bemiparin is combined with Labetalol.Approved, Investigational
BenazeprilBenazepril may increase the hypotensive activities of Labetalol.Approved, Investigational
BenazeprilatLabetalol may increase the hypotensive activities of Benazeprilat.Experimental
BencyclaneThe risk or severity of hypotension can be increased when Labetalol is combined with Bencyclane.Experimental
BendazacBendazac may decrease the antihypertensive activities of Labetalol.Experimental
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Labetalol.Approved
BenidipineThe risk or severity of hypotension can be increased when Labetalol is combined with Benidipine.Approved, Investigational
BenmoxinBenmoxin may increase the hypotensive activities of Labetalol.Withdrawn
BenorilateBenorilate may decrease the antihypertensive activities of Labetalol.Experimental
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Labetalol.Withdrawn
BenzphetamineThe therapeutic efficacy of Benzphetamine can be decreased when used in combination with Labetalol.Approved, Illicit
BenzydamineBenzydamine may decrease the antihypertensive activities of Labetalol.Approved
BepridilThe risk or severity of hypotension can be increased when Labetalol is combined with Bepridil.Approved, Withdrawn
BeractantLabetalol may increase the bradycardic activities of Beractant.Approved
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Labetalol.Approved, Investigational
BethanecholThe risk or severity of adverse effects can be increased when Labetalol is combined with Bethanechol.Approved
BethanidineThe therapeutic efficacy of Bethanidine can be decreased when used in combination with Labetalol.Approved
BevantololLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bevantolol.Approved
BietaserpineBietaserpine may increase the hypotensive activities of Labetalol.Experimental
BimatoprostLabetalol may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BioallethrinThe risk or severity of hypotension can be increased when Labetalol is combined with Bioallethrin.Approved, Experimental
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Labetalol.Approved
BitolterolThe therapeutic efficacy of Bitolterol can be decreased when used in combination with Labetalol.Withdrawn
BL-1020The serum concentration of Labetalol can be increased when it is combined with BL-1020.Investigational
BopindololBopindolol may increase the orthostatic hypotensive activities of Labetalol.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Labetalol.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Labetalol.Approved, Investigational
Bouteloua gracilis pollenThe risk of a hypersensitivity reaction to Bouteloua gracilis pollen is increased when it is combined with Labetalol.Approved
BQ-123Labetalol may increase the hypotensive activities of BQ-123.Investigational
BretyliumBretylium may increase the bradycardic activities of Labetalol.Approved
BrexpiprazoleLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the antihypertensive activities of Labetalol.Approved
BromfenacBromfenac may decrease the antihypertensive activities of Labetalol.Approved
BromocriptineLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.Approved, Investigational
BromotheophyllineThe risk or severity of adverse effects can be increased when Labetalol is combined with Bromotheophylline.Approved
Bromus secalinus pollenThe risk of a hypersensitivity reaction to Bromus secalinus pollen is increased when it is combined with Labetalol.Approved
BucindololLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bucindolol.Investigational
BufexamacBufexamac may decrease the antihypertensive activities of Labetalol.Approved, Experimental
BufuralolBufuralol may increase the orthostatic hypotensive activities of Labetalol.Experimental, Investigational
BufyllineThe risk or severity of adverse effects can be increased when Labetalol is combined with Bufylline.Experimental
BumadizoneBumadizone may decrease the antihypertensive activities of Labetalol.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Labetalol is combined with Bumetanide.Approved
BunazosinLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bunazosin.Investigational
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Labetalol.Approved, Investigational
BupranololBupranolol may increase the orthostatic hypotensive activities of Labetalol.Approved
BupropionThe metabolism of Labetalol can be decreased when combined with Bupropion.Approved
ButaperazineThe serum concentration of Labetalol can be increased when it is combined with Butaperazine.Experimental
CabergolineLabetalol may increase the vasoconstricting activities of Cabergoline.Approved
CadralazineCadralazine may increase the hypotensive activities of Labetalol.Experimental
CafedrineThe risk or severity of adverse effects can be increased when Labetalol is combined with Cafedrine.Investigational
CaffeineThe risk or severity of adverse effects can be increased when Labetalol is combined with Caffeine.Approved
CalfactantLabetalol may increase the bradycardic activities of Calfactant.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Labetalol is combined with Canagliflozin.Approved
CandesartanLabetalol may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilLabetalol may increase the hypotensive activities of Candesartan cilexetil.Approved
CandoxatrilLabetalol may increase the hypotensive activities of Candoxatril.Experimental
CannabidiolThe risk or severity of Tachycardia can be increased when Cannabidiol is combined with Labetalol.Approved, Investigational
CaptoprilLabetalol may increase the hypotensive activities of Captopril.Approved
CarbamoylcholineThe risk or severity of adverse effects can be increased when Labetalol is combined with Carbamoylcholine.Approved
Carbaspirin calciumCarbaspirin calcium may decrease the antihypertensive activities of Labetalol.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Labetalol.Approved, Investigational
CarboxyamidotriazoleThe risk or severity of hypotension can be increased when Labetalol is combined with Carboxyamidotriazole.Investigational
CarbutamideLabetalol may increase the hypoglycemic activities of Carbutamide.Experimental
CaroverineThe risk or severity of hypotension can be increased when Labetalol is combined with Caroverine.Experimental
CaroxazoneCaroxazone may increase the hypotensive activities of Labetalol.Withdrawn
CarprofenCarprofen may decrease the antihypertensive activities of Labetalol.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the orthostatic hypotensive activities of Labetalol.Approved
CarvedilolLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Carvedilol.Approved, Investigational
CelecoxibCelecoxib may decrease the antihypertensive activities of Labetalol.Approved, Investigational
CeliprololThe therapeutic efficacy of Celiprolol can be decreased when used in combination with Labetalol.Approved, Investigational
CeritinibLabetalol may increase the bradycardic activities of Ceritinib.Approved
CertoparinThe risk or severity of hyperkalemia can be increased when Certoparin is combined with Labetalol.Approved, Investigational
CevimelineThe risk or severity of adverse effects can be increased when Labetalol is combined with Cevimeline.Approved
ChloroquineThe risk or severity of QTc prolongation can be decreased when Chloroquine is combined with Labetalol.Approved, Investigational, Vet Approved
ChlorothiazideLabetalol may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphentermineThe risk or severity of adverse effects can be increased when Labetalol is combined with Chlorphentermine.Illicit, Withdrawn
ChlorproethazineThe serum concentration of Labetalol can be increased when it is combined with Chlorproethazine.Experimental
ChlorpromazineLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Chlorpromazine.Approved, Investigational, Vet Approved
ChlorpropamideLabetalol may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Labetalol.Approved
CholecalciferolThe metabolism of Labetalol can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the antihypertensive activities of Labetalol.Approved
CicletanineLabetalol may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilLabetalol may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of hypotension can be increased when Labetalol is combined with Cilnidipine.Approved, Investigational
CimetidineThe metabolism of Labetalol can be decreased when combined with Cimetidine.Approved, Investigational
CimicoxibCimicoxib may decrease the antihypertensive activities of Labetalol.Investigational
CinacalcetThe metabolism of Labetalol can be decreased when combined with Cinacalcet.Approved
CinnarizineThe risk or severity of hypotension can be increased when Labetalol is combined with Cinnarizine.Approved, Investigational
CirazolineThe therapeutic efficacy of Cirazoline can be decreased when used in combination with Labetalol.Experimental
ClemastineThe metabolism of Labetalol can be decreased when combined with Clemastine.Approved, Investigational
ClenbuterolThe therapeutic efficacy of Clenbuterol can be decreased when used in combination with Labetalol.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of hypotension can be increased when Labetalol is combined with Clevidipine.Approved, Investigational
ClobazamThe metabolism of Labetalol can be decreased when combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Labetalol.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Labetalol.Approved, Investigational, Vet Approved
ClonidineThe therapeutic efficacy of Clonidine can be decreased when used in combination with Labetalol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Labetalol.Approved
CloranololCloranolol may increase the orthostatic hypotensive activities of Labetalol.Experimental
ClozapineLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Clozapine.Approved
CobicistatThe serum concentration of Labetalol can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Labetalol can be decreased when combined with Cocaine.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Labetalol.Approved, Investigational
CoumaphosCoumaphos may increase the bradycardic activities of Labetalol.Vet Approved
CP-945598The risk or severity of Tachycardia can be increased when CP-945598 is combined with Labetalol.Investigational
CrizotinibLabetalol may increase the bradycardic activities of Crizotinib.Approved
CryptenamineLabetalol may increase the hypotensive activities of Cryptenamine.Approved
CurcuminThe metabolism of Labetalol can be decreased when combined with Curcumin.Approved, Investigational
CyamemazineThe serum concentration of Labetalol can be increased when it is combined with Cyamemazine.Approved
CyclandelateThe risk or severity of hypotension can be increased when Labetalol is combined with Cyclandelate.Approved
CyclopenthiazideLabetalol may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclosporineThe risk or severity of hyperkalemia can be increased when Labetalol is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideLabetalol may increase the hypotensive activities of Cyclothiazide.Approved
CymarinLabetalol may increase the bradycardic activities of Cymarin.Experimental
Cynodon dactylon pollenThe risk of a hypersensitivity reaction to Cynodon dactylon pollen is increased when it is combined with Labetalol.Approved
Dactylis glomerata pollenThe risk of a hypersensitivity reaction to Dactylis glomerata pollen is increased when it is combined with Labetalol.Approved
DalteparinThe risk or severity of hyperkalemia can be increased when Dalteparin is combined with Labetalol.Approved
DanaparoidThe risk or severity of hyperkalemia can be increased when Danaparoid is combined with Labetalol.Approved, Withdrawn
DapagliflozinThe risk or severity of adverse effects can be increased when Labetalol is combined with Dapagliflozin.Approved
DapiprazoleLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Dapiprazole.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Labetalol.Investigational
DarifenacinThe metabolism of Labetalol can be decreased when combined with Darifenacin.Approved, Investigational
DarodipineThe risk or severity of hypotension can be increased when Labetalol is combined with Darodipine.Experimental
DarunavirThe serum concentration of Labetalol can be increased when it is combined with Darunavir.Approved
DebrisoquinDebrisoquin may increase the hypotensive activities of Labetalol.Approved, Investigational
DecamethoniumDecamethonium may increase the bradycardic activities of Labetalol.Approved
DelaprilLabetalol may increase the hypotensive activities of Delapril.Investigational
DelavirdineThe metabolism of Labetalol can be decreased when combined with Delavirdine.Approved
DemecariumDemecarium may increase the bradycardic activities of Labetalol.Approved
DeserpidineLabetalol may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Labetalol.Approved
DeslanosideLabetalol may increase the bradycardic activities of Deslanoside.Approved
DesvenlafaxineThe serum concentration of Labetalol can be increased when it is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe therapeutic efficacy of Detomidine can be decreased when used in combination with Labetalol.Vet Approved
DexibuprofenDexibuprofen may decrease the antihypertensive activities of Labetalol.Approved, Investigational
DexketoprofenDexketoprofen may decrease the antihypertensive activities of Labetalol.Approved, Investigational
DexmedetomidineThe therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Labetalol.Approved, Vet Approved
DexniguldipineThe risk or severity of hypotension can be increased when Labetalol is combined with Dexniguldipine.Experimental
DextroamphetamineThe risk or severity of adverse effects can be increased when Labetalol is combined with Dextroamphetamine.Approved, Illicit
DexverapamilThe risk or severity of hypotension can be increased when Labetalol is combined with Dexverapamil.Experimental
DiazoxideDiazoxide may increase the hypotensive activities of Labetalol.Approved
DichlorvosDichlorvos may increase the bradycardic activities of Labetalol.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Labetalol.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Labetalol is combined with Diclofenamide.Approved, Investigational
DiethylnorspermineLabetalol may increase the hypotensive activities of Diethylnorspermine.Investigational
DiethylpropionThe risk or severity of adverse effects can be increased when Labetalol is combined with Diethylpropion.Approved, Illicit
DifenpiramideDifenpiramide may decrease the antihypertensive activities of Labetalol.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Labetalol.Approved, Investigational
DigitoxinLabetalol may increase the bradycardic activities of Digitoxin.Approved, Investigational
DigoxinLabetalol may increase the bradycardic activities of Digoxin.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Labetalol.Approved, Investigational
DihydroergocornineLabetalol may increase the vasoconstricting activities of Dihydroergocornine.Approved
DihydroergocristineLabetalol may increase the vasoconstricting activities of Dihydroergocristine.Approved, Experimental
DihydroergocryptineLabetalol may increase the vasoconstricting activities of Dihydroergocryptine.Experimental
DihydroergotamineLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Dihydroergotamine.Approved, Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Labetalol.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Labetalol is combined with Dinutuximab.Approved, Investigational
DiphenhydramineThe metabolism of Labetalol can be decreased when combined with Diphenhydramine.Approved, Investigational
DipivefrinThe therapeutic efficacy of Dipivefrin can be decreased when used in combination with Labetalol.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Labetalol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Labetalol.Approved
Distichlis spicata pollenThe risk of a hypersensitivity reaction to Distichlis spicata pollen is increased when it is combined with Labetalol.Approved
DistigmineDistigmine may increase the bradycardic activities of Labetalol.Experimental
DixyrazineThe serum concentration of Labetalol can be increased when it is combined with Dixyrazine.Experimental
DL-MethylephedrineThe therapeutic efficacy of DL-Methylephedrine can be decreased when used in combination with Labetalol.Approved
DobutamineThe therapeutic efficacy of Dobutamine can be decreased when used in combination with Labetalol.Approved
DonepezilDonepezil may increase the bradycardic activities of Labetalol.Approved
DopamineThe risk or severity of adverse effects can be increased when Labetalol is combined with Dopamine.Approved
DopexamineThe therapeutic efficacy of Dopexamine can be decreased when used in combination with Labetalol.Approved, Investigational
DorzolamideLabetalol may increase the hypotensive activities of Dorzolamide.Approved
DotarizineThe risk or severity of hypotension can be increased when Labetalol is combined with Dotarizine.Investigational
DoxazosinDoxazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Labetalol.Approved
DoxepinLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Doxepin.Approved, Investigational
DoxofyllineThe therapeutic efficacy of Doxofylline can be decreased when used in combination with Labetalol.Approved, Investigational
DronabinolThe risk or severity of Tachycardia can be increased when Dronabinol is combined with Labetalol.Approved, Illicit
DroperidolLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Droperidol.Approved, Vet Approved
DroxicamDroxicam may decrease the antihypertensive activities of Labetalol.Withdrawn
DroxidopaThe therapeutic efficacy of Droxidopa can be decreased when used in combination with Labetalol.Approved, Investigational
DuloxetineLabetalol may increase the orthostatic hypotensive activities of Duloxetine.Approved
EchothiophateEchothiophate may increase the bradycardic activities of Labetalol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Labetalol.Approved
EfonidipineThe risk or severity of hypotension can be increased when Labetalol is combined with Efonidipine.Approved, Investigational
Elymus repens pollenThe risk of a hypersensitivity reaction to Elymus repens pollen is increased when it is combined with Labetalol.Approved
EmopamilThe risk or severity of hypotension can be increased when Labetalol is combined with Emopamil.Experimental
EmpagliflozinThe risk or severity of adverse effects can be increased when Labetalol is combined with Empagliflozin.Approved
EnalaprilEnalapril may increase the hypotensive activities of Labetalol.Approved, Vet Approved
EnalaprilatLabetalol may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Labetalol.Experimental
EnoxaparinThe risk or severity of hyperkalemia can be increased when Enoxaparin is combined with Labetalol.Approved
EntecavirThe risk or severity of adverse effects can be increased when Labetalol is combined with Entecavir.Approved, Investigational
EpanololEpanolol may increase the orthostatic hypotensive activities of Labetalol.Experimental
EperisoneThe risk or severity of hypotension can be increased when Labetalol is combined with Eperisone.Approved, Investigational
EphedraThe therapeutic efficacy of Ephedra can be decreased when used in combination with Labetalol.Approved, Nutraceutical, Withdrawn
EphedrineThe therapeutic efficacy of Ephedrine can be decreased when used in combination with Labetalol.Approved
EpibatidineThe risk or severity of adverse effects can be increased when Labetalol is combined with Epibatidine.Experimental
EpinephrineThe therapeutic efficacy of Epinephrine can be decreased when used in combination with Labetalol.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Labetalol.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Labetalol is combined with Eplerenone.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Labetalol.Approved
EprosartanLabetalol may increase the hypotensive activities of Eprosartan.Approved
Ergoloid mesylateLabetalol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovineThe therapeutic efficacy of Ergonovine can be decreased when used in combination with Labetalol.Approved
ErgotamineLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Ergotamine.Approved
EsatenololEsatenolol may increase the orthostatic hypotensive activities of Labetalol.Experimental
EsmololEsmolol may increase the orthostatic hypotensive activities of Labetalol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Labetalol is combined with Etacrynic acid.Approved, Investigational
EtafedrineThe therapeutic efficacy of Etafedrine can be decreased when used in combination with Labetalol.Approved
EtamiphyllineThe risk or severity of adverse effects can be increased when Labetalol is combined with Etamiphylline.Experimental
EthenzamideEthenzamide may decrease the antihypertensive activities of Labetalol.Experimental
EthosuximideThe risk or severity of hypotension can be increased when Labetalol is combined with Ethosuximide.Approved
EtilefrineThe therapeutic efficacy of Etilefrine can be decreased when used in combination with Labetalol.Withdrawn
EtodolacEtodolac may decrease the antihypertensive activities of Labetalol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Labetalol.Approved, Investigational
EtomidateThe therapeutic efficacy of Etomidate can be decreased when used in combination with Labetalol.Approved
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Labetalol.Approved, Investigational
FelbinacFelbinac may decrease the antihypertensive activities of Labetalol.Experimental
FelodipineThe risk or severity of hypotension can be increased when Labetalol is combined with Felodipine.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Labetalol.Approved
FendilineThe risk or severity of hypotension can be increased when Labetalol is combined with Fendiline.Withdrawn
FenethyllineThe risk or severity of adverse effects can be increased when Labetalol is combined with Fenethylline.Approved
FenoldopamLabetalol may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Labetalol.Approved
FenoterolThe therapeutic efficacy of Fenoterol can be decreased when used in combination with Labetalol.Approved, Investigational
FenozoloneThe risk or severity of adverse effects can be increased when Labetalol is combined with Fenozolone.Experimental
FentanylFentanyl may increase the bradycardic activities of Labetalol.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Labetalol.Vet Approved
FentiazacFentiazac may decrease the antihypertensive activities of Labetalol.Experimental
FeprazoneFeprazone may decrease the antihypertensive activities of Labetalol.Experimental
Ferulic acidLabetalol may increase the hypotensive activities of Ferulic acid.Experimental
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Labetalol.Approved
Festuca pratensis pollenThe risk of a hypersensitivity reaction to Festuca pratensis pollen is increased when it is combined with Labetalol.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Labetalol.Approved, Investigational
FingolimodLabetalol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FirocoxibFirocoxib may decrease the antihypertensive activities of Labetalol.Experimental, Vet Approved
Fish oilThe risk or severity of hypotension can be increased when Labetalol is combined with Fish oil.Approved, Nutraceutical
FloctafenineThe risk or severity of adverse effects can be increased when Labetalol is combined with Floctafenine.Approved, Withdrawn
FluconazoleThe risk or severity of hyperkalemia can be increased when Fluconazole is combined with Labetalol.Approved, Investigational
FlunarizineThe risk or severity of hypotension can be increased when Labetalol is combined with Flunarizine.Approved
FlunixinFlunixin may decrease the antihypertensive activities of Labetalol.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the antihypertensive activities of Labetalol.Experimental
FluoxetineThe serum concentration of Labetalol can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Flupentixol.Approved, Investigational, Withdrawn
FluphenazineThe serum concentration of Labetalol can be increased when it is combined with Fluphenazine.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Labetalol.Approved, Investigational
FluspirileneThe risk or severity of hypotension can be increased when Labetalol is combined with Fluspirilene.Approved, Investigational
FluvoxamineThe metabolism of Labetalol can be decreased when combined with Fluvoxamine.Approved, Investigational
ForasartanThe risk or severity of hyperkalemia can be increased when Forasartan is combined with Labetalol.Experimental
FormoterolThe therapeutic efficacy of Formoterol can be decreased when used in combination with Labetalol.Approved, Investigational
FosinoprilFosinopril may increase the hypotensive activities of Labetalol.Approved
FosinoprilatLabetalol may increase the hypotensive activities of Fosinoprilat.Experimental
FostamatinibFostamatinib may increase the antihypertensive activities of Labetalol.Approved, Investigational
FurafyllineThe risk or severity of adverse effects can be increased when Labetalol is combined with Furafylline.Experimental
FurazolidoneFurazolidone may increase the hypotensive activities of Labetalol.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Labetalol is combined with Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of hypotension can be increased when Labetalol is combined with Gabapentin.Approved, Investigational
GalantamineGalantamine may increase the bradycardic activities of Labetalol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Labetalol.Approved
GallopamilThe risk or severity of hypotension can be increased when Labetalol is combined with Gallopamil.Investigational
GanciclovirThe risk or severity of adverse effects can be increased when Labetalol is combined with Ganciclovir.Approved, Investigational
GepefrineThe risk or severity of adverse effects can be increased when Labetalol is combined with Gepefrine.Experimental
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Labetalol.Approved, Investigational, Nutraceutical
GitoformateLabetalol may increase the bradycardic activities of Gitoformate.Experimental
GlibornurideLabetalol may increase the hypoglycemic activities of Glibornuride.Investigational, Withdrawn
GliclazideLabetalol may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideLabetalol may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideLabetalol may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GliquidoneLabetalol may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
GlisoxepideLabetalol may increase the hypoglycemic activities of Glisoxepide.Investigational
GlyburideLabetalol may increase the hypoglycemic activities of Glyburide.Approved
Glycerol PhenylbutyrateThe metabolism of Labetalol can be decreased when combined with Glycerol Phenylbutyrate.Approved
GTS-21The risk or severity of adverse effects can be increased when Labetalol is combined with GTS-21.Investigational
GuacetisalGuacetisal may decrease the antihypertensive activities of Labetalol.Experimental
GuanabenzThe therapeutic efficacy of Guanabenz can be decreased when used in combination with Labetalol.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Labetalol.Approved
GuanazodineLabetalol may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineLabetalol may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Labetalol.Approved, Investigational
GuanineThe risk or severity of adverse effects can be increased when Labetalol is combined with Guanine.Experimental
GuanoclorLabetalol may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzLabetalol may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanLabetalol may increase the hypotensive activities of Guanoxan.Experimental
GW842166The risk or severity of Tachycardia can be increased when GW842166 is combined with Labetalol.Investigational
HaloperidolThe metabolism of Labetalol can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Labetalol.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Labetalol.Experimental
HeparinThe risk or severity of hyperkalemia can be increased when Heparin is combined with Labetalol.Approved, Investigational
HexamethoniumLabetalol may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Labetalol.Approved
HexoprenalineThe therapeutic efficacy of Hexoprenaline can be decreased when used in combination with Labetalol.Approved, Withdrawn
HigenamineThe therapeutic efficacy of Higenamine can be decreased when used in combination with Labetalol.Investigational
Holcus lanatus pollenThe risk of a hypersensitivity reaction to Holcus lanatus pollen is increased when it is combined with Labetalol.Approved
Huperzine AHuperzine A may increase the bradycardic activities of Labetalol.Approved, Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Labetalol.Experimental
HydralazineHydralazine may increase the hypotensive activities of Labetalol.Approved
HydrochlorothiazideLabetalol may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Labetalol resulting in a loss in efficacy.Approved, Illicit
HydroflumethiazideLabetalol may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydroxyamphetamineThe risk or severity of adverse effects can be increased when Labetalol is combined with Hydroxyamphetamine.Approved
HydroxychloroquineThe risk or severity of QTc prolongation can be decreased when Hydroxychloroquine is combined with Labetalol.Approved
HypoxanthineThe risk or severity of adverse effects can be increased when Labetalol is combined with Hypoxanthine.Experimental
IbipinabantThe risk or severity of Tachycardia can be increased when Ibipinabant is combined with Labetalol.Investigational
IbuprofenIbuprofen may decrease the antihypertensive activities of Labetalol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Labetalol.Withdrawn
IcosapentIcosapent may decrease the antihypertensive activities of Labetalol.Approved, Nutraceutical
IloperidoneLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Iloperidone.Approved
IloprostIloprost may increase the hypotensive activities of Labetalol.Approved, Investigational
ImidaprilLabetalol may increase the hypotensive activities of Imidapril.Investigational
Imidazole salicylateImidazole salicylate may decrease the antihypertensive activities of Labetalol.Experimental
ImipramineLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Imipramine.Approved
IndacaterolThe therapeutic efficacy of Indacaterol can be decreased when used in combination with Labetalol.Approved
IndalpineThe serum concentration of Labetalol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndapamideLabetalol may increase the hypotensive activities of Indapamide.Approved
IndenololIndenolol may increase the orthostatic hypotensive activities of Labetalol.Withdrawn
IndobufenIndobufen may decrease the antihypertensive activities of Labetalol.Investigational
IndomethacinIndomethacin may decrease the antihypertensive activities of Labetalol.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Labetalol.Withdrawn
IndoraminLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.Withdrawn
Insulin AspartLabetalol may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DegludecLabetalol may increase the hypoglycemic activities of Insulin Degludec.Approved
Insulin DetemirLabetalol may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineLabetalol may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineLabetalol may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanLabetalol may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproLabetalol may increase the hypoglycemic activities of Insulin Lispro.Approved
Insulin peglisproLabetalol may increase the hypoglycemic activities of Insulin peglispro.Investigational
Insulin PorkLabetalol may increase the hypoglycemic activities of Insulin Pork.Approved
IobenguaneLabetalol can cause a decrease in the absorption of Iobenguane resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Iofetamine I-123The risk or severity of adverse effects can be increased when Labetalol is combined with Iofetamine I-123.Approved
IpidacrineIpidacrine may increase the bradycardic activities of Labetalol.Experimental
IproniazidIproniazid may increase the hypotensive activities of Labetalol.Withdrawn
IrbesartanLabetalol may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Labetalol.Approved
IsoetarineThe therapeutic efficacy of Isoetarine can be decreased when used in combination with Labetalol.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Labetalol.Approved, Vet Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Labetalol.Approved, Investigational, Withdrawn
IsomethepteneThe therapeutic efficacy of Isometheptene can be decreased when used in combination with Labetalol.Approved
IsoniazidThe metabolism of Labetalol can be decreased when combined with Isoniazid.Approved, Investigational
IsoprenalineThe therapeutic efficacy of Isoprenaline can be decreased when used in combination with Labetalol.Approved, Investigational
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Labetalol is combined with Isosorbide Dinitrate.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Labetalol is combined with Isosorbide Mononitrate.Approved
IsoxicamIsoxicam may decrease the antihypertensive activities of Labetalol.Withdrawn
IsoxsuprineThe therapeutic efficacy of Isoxsuprine can be decreased when used in combination with Labetalol.Approved, Withdrawn
IsradipineThe risk or severity of hypotension can be increased when Labetalol is combined with Isradipine.Approved, Investigational
ItoprideItopride may increase the bradycardic activities of Labetalol.Investigational
ItraconazoleThe risk or severity of hyperkalemia can be increased when Itraconazole is combined with Labetalol.Approved, Investigational
IvabradineLabetalol may increase the bradycardic activities of Ivabradine.Approved
KebuzoneKebuzone may decrease the antihypertensive activities of Labetalol.Experimental
KetanserinKetanserin may increase the hypotensive activities of Labetalol.Investigational
KetoconazoleThe risk or severity of hyperkalemia can be increased when Ketoconazole is combined with Labetalol.Approved, Investigational
KetoprofenKetoprofen may decrease the antihypertensive activities of Labetalol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Labetalol.Approved
Koeleria macrantha pollenThe risk of a hypersensitivity reaction to Koeleria macrantha pollen is increased when it is combined with Labetalol.Approved
LacidipineLabetalol may increase the hypotensive activities of Lacidipine.Approved, Investigational
LacosamideLabetalol may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
LamotrigineThe risk or severity of hypotension can be increased when Labetalol is combined with Lamotrigine.Approved, Investigational
Lanatoside CLabetalol may increase the bradycardic activities of Lanatoside C.Experimental
LandiololLandiolol may increase the orthostatic hypotensive activities of Labetalol.Investigational
LanreotideLabetalol may increase the bradycardic activities of Lanreotide.Approved
LatanoprostLabetalol may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipineThe risk or severity of hypotension can be increased when Labetalol is combined with Lercanidipine.Approved, Investigational
LevetiracetamThe risk or severity of hypotension can be increased when Labetalol is combined with Levetiracetam.Approved, Investigational
LevobetaxololLevobetaxolol may increase the orthostatic hypotensive activities of Labetalol.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Labetalol is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Labetalol.Approved, Investigational
LevodopaLabetalol may increase the orthostatic hypotensive activities of Levodopa.Approved
LevomilnacipranThe serum concentration of Labetalol can be increased when it is combined with Levomilnacipran.Approved, Investigational
LevosalbutamolThe therapeutic efficacy of Levosalbutamol can be decreased when used in combination with Labetalol.Approved, Investigational
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Labetalol.Approved, Investigational
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Labetalol.Approved, Vet Approved
LidoflazineThe risk or severity of hypotension can be increased when Labetalol is combined with Lidoflazine.Experimental
LinezolidThe risk or severity of hypertension can be increased when Linezolid is combined with Labetalol.Approved, Investigational
LinsidomineLabetalol may increase the hypotensive activities of Linsidomine.Experimental
LisdexamfetamineThe risk or severity of adverse effects can be increased when Labetalol is combined with Lisdexamfetamine.Approved, Investigational
LisinoprilLabetalol may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Labetalol is combined with Lisofylline.Investigational
LisurideLabetalol may increase the vasoconstricting activities of Lisuride.Approved, Investigational
LobelineThe risk or severity of adverse effects can be increased when Labetalol is combined with Lobeline.Investigational
LobucavirThe risk or severity of adverse effects can be increased when Labetalol is combined with Lobucavir.Investigational
LofexidineThe therapeutic efficacy of Lofexidine can be decreased when used in combination with Labetalol.Approved, Investigational
Lolium perenne pollenThe risk of a hypersensitivity reaction to Lolium perenne pollen is increased when it is combined with Labetalol.Approved
Lolium perenne subsp. multiflorum pollenThe risk of a hypersensitivity reaction to Lolium perenne subsp. multiflorum pollen is increased when it is combined with Labetalol.Approved
LomerizineThe risk or severity of hypotension can be increased when Labetalol is combined with Lomerizine.Experimental
LonazolacLonazolac may decrease the antihypertensive activities of Labetalol.Experimental
LoperamideThe risk or severity of hypotension can be increased when Labetalol is combined with Loperamide.Approved
LopinavirThe metabolism of Labetalol can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Labetalol can be decreased when combined with Lorcaserin.Approved
LornoxicamLornoxicam may decrease the antihypertensive activities of Labetalol.Approved, Investigational
LosartanLabetalol may increase the hypotensive activities of Losartan.Approved
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Labetalol.Approved, Investigational
LucinactantLabetalol may increase the bradycardic activities of Lucinactant.Approved, Investigational
LumefantrineThe metabolism of Labetalol can be decreased when combined with Lumefantrine.Approved
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Labetalol.Approved, Investigational
Lysergic Acid DiethylamideLabetalol may increase the vasoconstricting activities of Lysergic Acid Diethylamide.Illicit, Investigational, Withdrawn
MacitentanLabetalol may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Labetalol.Approved
Magnesium sulfateThe risk or severity of hypotension can be increased when Labetalol is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
MalathionMalathion may increase the bradycardic activities of Labetalol.Approved, Investigational
ManidipineThe risk or severity of hypotension can be increased when Labetalol is combined with Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Labetalol is combined with Mannitol.Approved, Investigational
Mannitol busulfanThe risk or severity of hyperkalemia can be increased when Labetalol is combined with Mannitol busulfan.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Labetalol.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Labetalol.Approved, Investigational
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Labetalol.Approved, Vet Approved
MedetomidineThe therapeutic efficacy of Medetomidine can be decreased when used in combination with Labetalol.Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Labetalol.Approved
MefenorexThe risk or severity of adverse effects can be increased when Labetalol is combined with Mefenorex.Experimental
MefloquineThe risk or severity of QTc prolongation can be decreased when Mefloquine is combined with Labetalol.Approved, Investigational
MeloxicamMeloxicam may decrease the antihypertensive activities of Labetalol.Approved, Vet Approved
MentholThe risk or severity of hypotension can be increased when Labetalol is combined with Menthol.Approved
MephedroneThe risk or severity of adverse effects can be increased when Labetalol is combined with Mephedrone.Investigational
MephentermineThe therapeutic efficacy of Mephentermine can be decreased when used in combination with Labetalol.Approved
MepindololMepindolol may increase the orthostatic hypotensive activities of Labetalol.Experimental
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Labetalol.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Labetalol.Approved
MesoridazineThe serum concentration of Labetalol can be increased when it is combined with Mesoridazine.Approved, Investigational
MetahexamideLabetalol may increase the hypoglycemic activities of Metahexamide.Experimental
MetamizoleMetamizole may decrease the antihypertensive activities of Labetalol.Approved, Investigational, Withdrawn
MetaraminolThe therapeutic efficacy of Metaraminol can be decreased when used in combination with Labetalol.Approved, Investigational
MetergolineLabetalol may increase the vasoconstricting activities of Metergoline.Experimental
MethacholineLabetalol may increase the bronchoconstrictory activities of Methacholine.Approved, Investigational
MethadoneThe metabolism of Labetalol can be decreased when combined with Methadone.Approved
MethamphetamineThe therapeutic efficacy of Methamphetamine can be decreased when used in combination with Labetalol.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Labetalol.Investigational
MethazolamideThe risk or severity of adverse effects can be increased when Labetalol is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Labetalol.Approved
MethoserpidineLabetalol may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Methotrimeprazine.Approved, Investigational
MethoxamineThe therapeutic efficacy of Methoxamine can be decreased when used in combination with Labetalol.Approved, Investigational
MethoxyphenamineThe therapeutic efficacy of Methoxyphenamine can be decreased when used in combination with Labetalol.Experimental
MethsuximideThe risk or severity of hypotension can be increased when Labetalol is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Labetalol.Approved
MethyldopaThe therapeutic efficacy of Methyldopa can be decreased when used in combination with Labetalol.Approved
Methylene blueThe serum concentration of Labetalol can be increased when it is combined with Methylene blue.Approved, Investigational
MethylergometrineLabetalol may increase the vasoconstricting activities of Methylergometrine.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Labetalol.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Labetalol.Approved
MethysergideLabetalol may increase the vasoconstricting activities of Methysergide.Approved
MetildigoxinLabetalol may increase the bradycardic activities of Metildigoxin.Experimental
MetipranololLabetalol may increase the hypotensive activities of Metipranolol.Approved
MetoclopramideMetoclopramide may increase the bradycardic activities of Labetalol.Approved, Investigational
MetolazoneMetolazone may increase the hypotensive activities of Labetalol.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Labetalol.Approved, Investigational
MetyrosineLabetalol may increase the hypotensive activities of Metyrosine.Approved
MibefradilThe risk or severity of hypotension can be increased when Labetalol is combined with Mibefradil.Investigational, Withdrawn
MidomafetamineThe risk or severity of adverse effects can be increased when Labetalol is combined with Midomafetamine.Experimental, Illicit, Investigational
MilnacipranThe serum concentration of Labetalol can be increased when it is combined with Milnacipran.Approved, Investigational
MinaprineMinaprine may increase the bradycardic activities of Labetalol.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Labetalol.Approved, Investigational
MirabegronThe therapeutic efficacy of Mirabegron can be decreased when used in combination with Labetalol.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Labetalol.Investigational
MMDAThe risk or severity of adverse effects can be increased when Labetalol is combined with MMDA.Experimental, Illicit
MoclobemideMoclobemide may increase the hypotensive activities of Labetalol.Approved, Investigational
MoexiprilLabetalol may increase the hypotensive activities of Moexipril.Approved
MofebutazoneMofebutazone may decrease the antihypertensive activities of Labetalol.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Labetalol.Approved, Investigational
MoricizineThe serum concentration of Labetalol can be increased when it is combined with Moricizine.Approved, Investigational, Withdrawn
MorniflumateMorniflumate may decrease the antihypertensive activities of Labetalol.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Labetalol.Approved, Investigational
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Labetalol.Approved, Investigational
MuzolimineLabetalol may increase the hypotensive activities of Muzolimine.Experimental
NabiloneThe risk or severity of Tachycardia can be increased when Nabilone is combined with Labetalol.Approved, Investigational
NabiximolsThe risk or severity of Tachycardia can be increased when Nabiximols is combined with Labetalol.Approved, Investigational
NabumetoneNabumetone may decrease the antihypertensive activities of Labetalol.Approved
NadololNadolol may increase the orthostatic hypotensive activities of Labetalol.Approved
NadroparinThe risk or severity of hyperkalemia can be increased when Nadroparin is combined with Labetalol.Approved, Investigational
NaftopidilThe risk or severity of hypotension can be increased when Labetalol is combined with Naftopidil.Investigational
NaphazolineThe therapeutic efficacy of Naphazoline can be decreased when used in combination with Labetalol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Labetalol.Approved, Vet Approved
NebivololThe therapeutic efficacy of Nebivolol can be decreased when used in combination with Labetalol.Approved, Investigational
NefazodoneLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Nefazodone.Approved, Withdrawn
NeostigmineNeostigmine may increase the bradycardic activities of Labetalol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Labetalol.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Labetalol is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Labetalol.Withdrawn
NicardipineLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Nicardipine.Approved, Investigational
NicergolineLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Nicergoline.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Labetalol.Approved, Investigational
NicotineThe risk or severity of adverse effects can be increased when Labetalol is combined with Nicotine.Approved
NifedipineThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Labetalol.Approved
NifenazoneNifenazone may decrease the antihypertensive activities of Labetalol.Experimental
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Labetalol.Approved
NiguldipineLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Niguldipine.Experimental
NilotinibThe metabolism of Labetalol can be decreased when combined with Nilotinib.Approved, Investigational
NiludipineThe risk or severity of hypotension can be increased when Labetalol is combined with Niludipine.Experimental
NilvadipineThe risk or severity of hypotension can be increased when Labetalol is combined with Nilvadipine.Approved, Investigational
NimesulideNimesulide may decrease the antihypertensive activities of Labetalol.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of hypotension can be increased when Labetalol is combined with Nimodipine.Approved, Investigational
NisoldipineThe risk or severity of hypotension can be increased when Labetalol is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of hypotension can be increased when Labetalol is combined with Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Labetalol.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Labetalol.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Labetalol is combined with Nitroglycerin.Approved, Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Labetalol.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Nitrous acid is combined with Labetalol.Approved, Investigational
NN344Labetalol may increase the hypoglycemic activities of NN344.Investigational
NorepinephrineThe therapeutic efficacy of Norepinephrine can be decreased when used in combination with Labetalol.Approved
NorfenefrineThe therapeutic efficacy of Norfenefrine can be decreased when used in combination with Labetalol.Experimental
NortriptylineLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Nortriptyline.Approved
NS-398NS-398 may decrease the antihypertensive activities of Labetalol.Experimental
NylidrinThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Labetalol.Approved
ObinutuzumabLabetalol may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Labetalol.Withdrawn
OctopamineThe therapeutic efficacy of Octopamine can be decreased when used in combination with Labetalol.Experimental
OctreotideOctreotide may increase the bradycardic activities of Labetalol.Approved, Investigational
OlanzapineLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Olanzapine.Approved, Investigational
OleandrinLabetalol may increase the bradycardic activities of Oleandrin.Experimental, Investigational
OlmesartanOlmesartan may increase the hypotensive activities of Labetalol.Approved, Investigational
OlodaterolThe therapeutic efficacy of Olodaterol can be decreased when used in combination with Labetalol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Labetalol.Approved
OmapatrilatLabetalol may increase the hypotensive activities of Omapatrilat.Investigational
OrciprenalineThe therapeutic efficacy of Orciprenaline can be decreased when used in combination with Labetalol.Approved
OtiloniumThe risk or severity of hypotension can be increased when Labetalol is combined with Otilonium.Experimental, Investigational
OuabainLabetalol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Labetalol.Approved
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Labetalol.Approved
OxtriphyllineThe risk or severity of adverse effects can be increased when Labetalol is combined with Oxtriphylline.Approved
OxyfedrineThe therapeutic efficacy of Oxyfedrine can be decreased when used in combination with Labetalol.Experimental
OxymetazolineThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Labetalol.Approved, Investigational
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Labetalol.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Labetalol.Approved, Vet Approved
PaliperidoneLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.Approved
PalmidrolThe risk or severity of Tachycardia can be increased when Palmidrol is combined with Labetalol.Experimental, Nutraceutical
PanobinostatThe serum concentration of Labetalol can be increased when it is combined with Panobinostat.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Labetalol is combined with Papaverine.Approved, Investigational
ParaoxonParaoxon may increase the bradycardic activities of Labetalol.Experimental
ParecoxibParecoxib may decrease the antihypertensive activities of Labetalol.Approved
PargylinePargyline may increase the hypotensive activities of Labetalol.Approved
ParnaparinThe risk or severity of hyperkalemia can be increased when Parnaparin is combined with Labetalol.Approved, Investigational
ParoxetineThe serum concentration of Labetalol can be increased when it is combined with Paroxetine.Approved, Investigational
Pascopyrum smithii pollenThe risk of a hypersensitivity reaction to Pascopyrum smithii pollen is increased when it is combined with Labetalol.Approved
PasireotideLabetalol may increase the bradycardic activities of Pasireotide.Approved
Paspalum notatum pollenThe risk of a hypersensitivity reaction to Paspalum notatum pollen is increased when it is combined with Labetalol.Approved
Patent BlueThe risk or severity of hypersensitivity reaction can be increased when Patent Blue is combined with Labetalol.Approved
Peginterferon alfa-2bThe serum concentration of Labetalol can be decreased when it is combined with Peginterferon alfa-2b.Approved
PeldesineThe risk or severity of adverse effects can be increased when Labetalol is combined with Peldesine.Experimental, Investigational
PemetrexedThe risk or severity of adverse effects can be increased when Labetalol is combined with Pemetrexed.Approved, Investigational
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Labetalol.Approved, Investigational
PenciclovirThe risk or severity of adverse effects can be increased when Labetalol is combined with Penciclovir.Approved
PenfluridolThe risk or severity of hypotension can be increased when Labetalol is combined with Penfluridol.Experimental
Penicillin G Acyl-SerineThe risk or severity of hyperkalemia can be increased when Labetalol is combined with Penicillin G Acyl-Serine.Experimental
PentamidineThe risk or severity of hyperkalemia can be increased when Labetalol is combined with Pentamidine.Approved, Investigational
PentifyllineThe risk or severity of adverse effects can be increased when Labetalol is combined with Pentifylline.Experimental
PentobarbitalPentobarbital may increase the hypotensive activities of Labetalol.Approved, Investigational, Vet Approved
PentoliniumLabetalol may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Labetalol.Approved, Investigational
PerazineThe serum concentration of Labetalol can be increased when it is combined with Perazine.Approved, Investigational
PergolideThe therapeutic efficacy of Pergolide can be decreased when used in combination with Labetalol.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilLabetalol may increase the hypotensive activities of Perindopril.Approved
PerindoprilatLabetalol may increase the hypotensive activities of Perindoprilat.Experimental
PerphenazineThe serum concentration of Labetalol can be increased when it is combined with Perphenazine.Approved
PeruvosideLabetalol may increase the bradycardic activities of Peruvoside.Experimental
PF-00610355The therapeutic efficacy of PF-00610355 can be decreased when used in combination with Labetalol.Investigational
Phalaris arundinacea pollenThe risk of a hypersensitivity reaction to Phalaris arundinacea pollen is increased when it is combined with Labetalol.Approved
Phalaris minor pollenThe risk of a hypersensitivity reaction to Phalaris minor pollen is increased when it is combined with Labetalol.Approved
PhendimetrazineThe therapeutic efficacy of Phendimetrazine can be decreased when used in combination with Labetalol.Approved, Illicit
PhenelzinePhenelzine may increase the hypotensive activities of Labetalol.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Labetalol.Withdrawn
PhenmetrazineThe risk or severity of adverse effects can be increased when Labetalol is combined with Phenmetrazine.Approved, Illicit
PhenobarbitalPhenobarbital may increase the hypotensive activities of Labetalol.Approved, Investigational
PhenoxybenzamineLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Labetalol.Withdrawn
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Labetalol.Approved, Illicit
PhentolamineLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Phentolamine.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Labetalol.Approved, Vet Approved
Phenylbutyric acidThe metabolism of Labetalol can be decreased when combined with Phenylbutyric acid.Approved, Investigational
PhenylephrineThe therapeutic efficacy of Phenylephrine can be decreased when used in combination with Labetalol.Approved
PhenylpropanolamineThe therapeutic efficacy of Phenylpropanolamine can be decreased when used in combination with Labetalol.Approved, Vet Approved, Withdrawn
Phleum pratense pollenThe risk of a hypersensitivity reaction to Phleum pratense pollen is increased when it is combined with Labetalol.Approved, Investigational
PhysostigminePhysostigmine may increase the bradycardic activities of Labetalol.Approved, Investigational
PilocarpineThe risk or severity of adverse effects can be increased when Labetalol is combined with Pilocarpine.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Labetalol.Approved
PinaveriumThe risk or severity of hypotension can be increased when Labetalol is combined with Pinaverium.Approved
PindololPindolol may increase the orthostatic hypotensive activities of Labetalol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Labetalol.Approved, Investigational
PipotiazineThe serum concentration of Labetalol can be increased when it is combined with Pipotiazine.Approved, Investigational
PirbuterolThe therapeutic efficacy of Pirbuterol can be decreased when used in combination with Labetalol.Approved
PirlindolePirlindole may increase the hypotensive activities of Labetalol.Approved
PiroxicamPiroxicam may decrease the antihypertensive activities of Labetalol.Approved, Investigational
PirprofenPirprofen may decrease the antihypertensive activities of Labetalol.Experimental
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Labetalol.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Labetalol.Withdrawn
PizotifenLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Pizotifen.Approved
Poa annua pollenThe risk of a hypersensitivity reaction to Poa annua pollen is increased when it is combined with Labetalol.Approved
Poa compressa pollenThe risk of a hypersensitivity reaction to Poa compressa pollen is increased when it is combined with Labetalol.Approved
Poa pratensis pollenThe risk of a hypersensitivity reaction to Poa pratensis pollen is increased when it is combined with Labetalol.Approved
PolythiazideLabetalol may increase the hypotensive activities of Polythiazide.Approved
Poractant alfaLabetalol may increase the bradycardic activities of Poractant alfa.Approved
Potassium acetateThe risk or severity of hyperkalemia can be increased when Potassium acetate is combined with Labetalol.Approved, Investigational
Potassium bicarbonateThe risk or severity of hyperkalemia can be increased when Potassium bicarbonate is combined with Labetalol.Approved
Potassium cationThe risk or severity of hyperkalemia can be increased when Potassium cation is combined with Labetalol.Approved, Investigational
Potassium ChlorideThe risk or severity of hyperkalemia can be increased when Potassium Chloride is combined with Labetalol.Approved, Withdrawn
Potassium CitrateThe risk or severity of hyperkalemia can be increased when Potassium Citrate is combined with Labetalol.Approved, Investigational, Vet Approved
PractololPractolol may increase the orthostatic hypotensive activities of Labetalol.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Labetalol.Approved, Investigational
PranoprofenPranoprofen may decrease the antihypertensive activities of Labetalol.Experimental, Investigational
PrazosinPrazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Labetalol.Approved
PrenalterolThe therapeutic efficacy of Prenalterol can be decreased when used in combination with Labetalol.Experimental
PrenylamineThe risk or severity of hypotension can be increased when Labetalol is combined with Prenylamine.Withdrawn
PrimaquineThe risk or severity of QTc prolongation can be decreased when Primaquine is combined with Labetalol.Approved
PrimidonePrimidone may increase the hypotensive activities of Labetalol.Approved, Vet Approved
ProcaterolThe therapeutic efficacy of Procaterol can be decreased when used in combination with Labetalol.Approved, Investigational
ProchlorperazineThe serum concentration of Labetalol can be increased when it is combined with Prochlorperazine.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the antihypertensive activities of Labetalol.Experimental
PromazineLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Promazine.Approved, Vet Approved
PromethazineThe serum concentration of Labetalol can be increased when it is combined with Promethazine.Approved, Investigational
PropacetamolPropacetamol may decrease the antihypertensive activities of Labetalol.Approved, Investigational
PropafenoneThe risk or severity of adverse effects can be increased when Propafenone is combined with Labetalol.Approved
PropentofyllineThe risk or severity of adverse effects can be increased when Labetalol is combined with Propentofylline.Investigational
PropericiazineLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Propericiazine.Approved, Investigational
PropiomazineLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Propiomazine.Approved
PropiopromazineThe serum concentration of Labetalol can be increased when it is combined with Propiopromazine.Vet Approved
PropiverineLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Propiverine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Labetalol.Approved, Investigational, Vet Approved
PropranololPropranolol may increase the orthostatic hypotensive activities of Labetalol.Approved, Investigational
PropyphenazonePropyphenazone may decrease the antihypertensive activities of Labetalol.Experimental
ProquazoneProquazone may decrease the antihypertensive activities of Labetalol.Experimental
ProscillaridinLabetalol may increase the bradycardic activities of Proscillaridin.Experimental
ProtokylolThe therapeutic efficacy of Protokylol can be decreased when used in combination with Labetalol.Approved, Vet Approved
ProxyphyllineThe risk or severity of adverse effects can be increased when Labetalol is combined with Proxyphylline.Experimental
PseudoephedrineThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Labetalol.Approved
PyridostigminePyridostigmine may increase the bradycardic activities of Labetalol.Approved, Investigational
QuetiapineLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Quetiapine.Approved
QuinaprilLabetalol may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinaprilatLabetalol may increase the hypotensive activities of Quinaprilat.Experimental
QuinidineLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Quinidine.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Labetalol.Approved
RacepinephrineThe therapeutic efficacy of Racepinephrine can be decreased when used in combination with Labetalol.Approved
RactopamineThe therapeutic efficacy of Ractopamine can be decreased when used in combination with Labetalol.Vet Approved
RamiprilRamipril may increase the hypotensive activities of Labetalol.Approved
RamiprilatLabetalol may increase the hypotensive activities of Ramiprilat.Experimental
RasagilineRasagiline may increase the hypotensive activities of Labetalol.Approved
RegorafenibRegorafenib may increase the bradycardic activities of Labetalol.Approved
RemifentanilRemifentanil may increase the bradycardic activities of Labetalol.Approved
RemikirenRemikiren may increase the hypotensive activities of Labetalol.Approved
ReproterolThe therapeutic efficacy of Reproterol can be decreased when used in combination with Labetalol.Investigational
RescinnamineLabetalol may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Labetalol.Approved, Investigational
ReviparinThe risk or severity of hyperkalemia can be increased when Reviparin is combined with Labetalol.Approved, Investigational
RheinThe metabolism of Labetalol can be decreased when combined with Rhein.Experimental
RilmenidineThe therapeutic efficacy of Rilmenidine can be decreased when used in combination with Labetalol.Approved, Investigational
RimiterolThe therapeutic efficacy of Rimiterol can be decreased when used in combination with Labetalol.Experimental
RimonabantThe risk or severity of Tachycardia can be increased when Rimonabant is combined with Labetalol.Approved, Investigational
RiociguatLabetalol may increase the hypotensive activities of Riociguat.Approved
RitanserinThe serum concentration of Labetalol can be increased when it is combined with Ritanserin.Investigational
RitobegronThe therapeutic efficacy of Ritobegron can be decreased when used in combination with Labetalol.Investigational
RitodrineThe therapeutic efficacy of Ritodrine can be decreased when used in combination with Labetalol.Approved, Investigational
RitonavirThe metabolism of Labetalol can be decreased when combined with Ritonavir.Approved, Investigational
RituximabLabetalol may increase the hypotensive activities of Rituximab.Approved
RivastigmineLabetalol may increase the bradycardic activities of Rivastigmine.Approved, Investigational
RobenacoxibRobenacoxib may decrease the antihypertensive activities of Labetalol.Experimental, Vet Approved
RofecoxibRofecoxib may decrease the antihypertensive activities of Labetalol.Approved, Investigational, Withdrawn
RolapitantThe metabolism of Labetalol can be decreased when combined with Rolapitant.Approved, Investigational
RomifidineThe therapeutic efficacy of Romifidine can be decreased when used in combination with Labetalol.Vet Approved
RopiniroleThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Labetalol.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Labetalol.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Labetalol.Approved
RucaparibThe metabolism of Labetalol can be decreased when combined with Rucaparib.Approved, Investigational
RuxolitinibRuxolitinib may increase the bradycardic activities of Labetalol.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Labetalol.Approved
SafinamideSafinamide may increase the hypotensive activities of Labetalol.Approved, Investigational
SafrazineSafrazine may increase the hypotensive activities of Labetalol.Withdrawn
SalbutamolThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Labetalol.Approved, Vet Approved
SalicylamideSalicylamide may decrease the antihypertensive activities of Labetalol.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Labetalol.Approved, Investigational, Vet Approved
SalmeterolThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Labetalol.Approved
SalsalateSalsalate may decrease the antihypertensive activities of Labetalol.Approved
SaprisartanLabetalol may increase the hypotensive activities of Saprisartan.Experimental
SaralasinThe risk or severity of hyperkalemia can be increased when Saralasin is combined with Labetalol.Investigational
SC-236SC-236 may decrease the antihypertensive activities of Labetalol.Experimental, Investigational
Secale cereale pollenThe risk of a hypersensitivity reaction to Secale cereale pollen is increased when it is combined with Labetalol.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Labetalol.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Labetalol.Approved, Investigational, Vet Approved
SeletracetamThe risk or severity of hypotension can be increased when Labetalol is combined with Seletracetam.Investigational
SelexipagLabetalol may increase the hypotensive activities of Selexipag.Approved
SertralineThe serum concentration of Labetalol can be increased when it is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Labetalol.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Labetalol.Approved, Investigational
SilodosinLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Silodosin.Approved
SitaxentanLabetalol may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SLV319The risk or severity of Tachycardia can be increased when SLV319 is combined with Labetalol.Investigational
SolabegronThe therapeutic efficacy of Solabegron can be decreased when used in combination with Labetalol.Investigational
Sorghum bicolor subsp. drummondii pollenThe risk of a hypersensitivity reaction to Sorghum bicolor subsp. drummondii pollen is increased when it is combined with Labetalol.Approved
Sorghum halepense pollenThe risk of a hypersensitivity reaction to Sorghum halepense pollen is increased when it is combined with Labetalol.Approved
SotalolSotalol may increase the orthostatic hypotensive activities of Labetalol.Approved
SpiraprilLabetalol may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Labetalol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Labetalol.Approved, Investigational
SuccinylcholineThe risk or severity of hyperkalemia can be increased when Labetalol is combined with Succinylcholine.Approved
SufentanilSufentanil may increase the bradycardic activities of Labetalol.Approved, Investigational
SulconazoleThe metabolism of Labetalol can be decreased when combined with Sulconazole.Approved
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Labetalol.Approved
SulindacSulindac may decrease the antihypertensive activities of Labetalol.Approved, Investigational
SulodexideThe risk or severity of hyperkalemia can be increased when Sulodexide is combined with Labetalol.Approved, Investigational
SuprofenSuprofen may decrease the antihypertensive activities of Labetalol.Approved, Withdrawn
SurinabantThe risk or severity of Tachycardia can be increased when Surinabant is combined with Labetalol.Investigational
SuxibuzoneSuxibuzone may decrease the antihypertensive activities of Labetalol.Experimental
SynephrineThe therapeutic efficacy of Synephrine can be decreased when used in combination with Labetalol.Experimental
TacrineTacrine may increase the bradycardic activities of Labetalol.Investigational, Withdrawn
TacrolimusThe risk or severity of hyperkalemia can be increased when Labetalol is combined with Tacrolimus.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Labetalol.Approved, Investigational
TalinololTalinolol may increase the orthostatic hypotensive activities of Labetalol.Investigational
TalniflumateTalniflumate may decrease the antihypertensive activities of Labetalol.Approved
TamsulosinLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Tamsulosin.Approved, Investigational
TasosartanThe risk or severity of hyperkalemia can be increased when Tasosartan is combined with Labetalol.Approved
Tedizolid phosphateTedizolid phosphate may increase the hypertensive activities of Labetalol.Approved
TelmisartanLabetalol may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilLabetalol may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenidapTenidap may decrease the antihypertensive activities of Labetalol.Experimental
TenoxicamTenoxicam may decrease the antihypertensive activities of Labetalol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Labetalol.Vet Approved
TerazosinLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Terazosin.Approved
TerbinafineThe metabolism of Labetalol can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineThe therapeutic efficacy of Terbutaline can be decreased when used in combination with Labetalol.Approved
TergurideLabetalol may increase the vasoconstricting activities of Terguride.Experimental
TerodilineThe risk or severity of hypotension can be increased when Labetalol is combined with Terodiline.Experimental
TertatololTertatolol may increase the orthostatic hypotensive activities of Labetalol.Experimental
TetrahydropalmatineThe risk or severity of hypotension can be increased when Labetalol is combined with Tetrahydropalmatine.Investigational
TetrandrineThe risk or severity of hypotension can be increased when Labetalol is combined with Tetrandrine.Experimental
TetryzolineThe therapeutic efficacy of Tetryzoline can be decreased when used in combination with Labetalol.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Labetalol.Approved, Investigational, Withdrawn
TheobromineThe risk or severity of adverse effects can be increased when Labetalol is combined with Theobromine.Approved, Investigational
TheodrenalineThe risk or severity of adverse effects can be increased when Labetalol is combined with Theodrenaline.Investigational
TheophyllineTheophylline may increase the antihypertensive activities of Labetalol.Approved
ThiamylalThiamylal may increase the hypotensive activities of Labetalol.Approved, Vet Approved
ThiazinamThe serum concentration of Labetalol can be increased when it is combined with Thiazinam.Experimental
ThiethylperazineThe serum concentration of Labetalol can be increased when it is combined with Thiethylperazine.Withdrawn
ThiopentalThiopental may increase the hypotensive activities of Labetalol.Approved, Vet Approved
ThioproperazineLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Thioproperazine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Labetalol.Approved, Withdrawn
ThiothixeneThe metabolism of Labetalol can be decreased when combined with Thiothixene.Approved
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Labetalol.Approved
TicagrelorThe metabolism of Labetalol can be decreased when combined with Ticagrelor.Approved
TicrynafenLabetalol may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the orthostatic hypotensive activities of Labetalol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Labetalol.Investigational
TinzaparinThe risk or severity of hyperkalemia can be increased when Tinzaparin is combined with Labetalol.Approved
TipranavirThe metabolism of Labetalol can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe therapeutic efficacy of Tizanidine can be decreased when used in combination with Labetalol.Approved, Investigational
TocopherylquinoneLabetalol may increase the hypotensive activities of Tocopherylquinone.Experimental, Investigational
TofacitinibTofacitinib may increase the bradycardic activities of Labetalol.Approved, Investigational
TolazamideLabetalol may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolazolineLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Tolazoline.Approved, Vet Approved
TolbutamideLabetalol may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Labetalol.Approved, Withdrawn
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Labetalol.Approved, Investigational
TolmetinTolmetin may decrease the antihypertensive activities of Labetalol.Approved
TolonidineLabetalol may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Labetalol.Approved
TorasemideTorasemide may increase the hypotensive activities of Labetalol.Approved
TramazolineThe risk or severity of adverse effects can be increased when Labetalol is combined with Tramazoline.Investigational
TrandolaprilTrandolapril may increase the hypotensive activities of Labetalol.Approved
TranilastThe risk or severity of hypotension can be increased when Labetalol is combined with Tranilast.Approved, Investigational
TranylcypromineTranylcypromine may increase the hypotensive activities of Labetalol.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Labetalol.Approved
TrazodoneLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Trazodone.Approved, Investigational
TreprostinilTreprostinil may increase the hypotensive activities of Labetalol.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Labetalol.Approved, Investigational, Nutraceutical
TretoquinolThe therapeutic efficacy of Tretoquinol can be decreased when used in combination with Labetalol.Experimental
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Labetalol.Approved
TrichlorfonTrichlorfon may increase the bradycardic activities of Labetalol.Vet Approved
TrichlormethiazideLabetalol may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Trifluoperazine.Approved, Investigational
TriflupromazineThe serum concentration of Labetalol can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimazosinLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Trimazosin.Experimental
TrimebutineThe risk or severity of hypotension can be increased when Labetalol is combined with Trimebutine.Approved
TrimethadioneThe risk or severity of hypotension can be increased when Labetalol is combined with Trimethadione.Approved
TrimethaphanTrimethaphan may increase the hypotensive activities of Labetalol.Approved, Investigational
TrimethoprimThe risk or severity of hyperkalemia can be increased when Labetalol is combined with Trimethoprim.Approved, Vet Approved
TrimipramineLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Trimipramine.Approved
Trolamine salicylateTrolamine salicylate may decrease the antihypertensive activities of Labetalol.Approved
TubocurarineTubocurarine may increase the bradycardic activities of Labetalol.Approved
TulobuterolThe therapeutic efficacy of Tulobuterol can be decreased when used in combination with Labetalol.Investigational
TyramineThe risk or severity of adverse effects can be increased when Labetalol is combined with Tyramine.Investigational, Nutraceutical
TyrothricinTyrothricin may increase the bradycardic activities of Labetalol.Approved
UdenafilUdenafil may increase the antihypertensive activities of Labetalol.Approved, Investigational
UnoprostoneLabetalol may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Urapidil.Investigational
Uric AcidThe risk or severity of adverse effects can be increased when Labetalol is combined with Uric Acid.Experimental, Investigational
Urochloa mutica pollenThe risk of a hypersensitivity reaction to Urochloa mutica pollen is increased when it is combined with Labetalol.Approved
ValaciclovirThe risk or severity of adverse effects can be increased when Labetalol is combined with Valaciclovir.Approved, Investigational
ValdecoxibValdecoxib may decrease the antihypertensive activities of Labetalol.Approved, Investigational, Withdrawn
ValganciclovirThe risk or severity of adverse effects can be increased when Labetalol is combined with Valganciclovir.Approved, Investigational
ValomaciclovirThe risk or severity of adverse effects can be increased when Labetalol is combined with Valomaciclovir.Investigational
ValsartanValsartan may increase the hypotensive activities of Labetalol.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Labetalol.Approved
VareniclineThe risk or severity of adverse effects can be increased when Labetalol is combined with Varenicline.Approved, Investigational
VenlafaxineThe serum concentration of Labetalol can be increased when it is combined with Venlafaxine.Approved
VerapamilLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.Approved
VilanterolThe therapeutic efficacy of Vilanterol can be decreased when used in combination with Labetalol.Approved
VilazodoneThe metabolism of Labetalol can be decreased when combined with Vilazodone.Approved
VincamineLabetalol may increase the hypotensive activities of Vincamine.Experimental
VinpocetineThe risk or severity of hypotension can be increased when Labetalol is combined with Vinpocetine.Investigational
WIN 55212-2The risk or severity of hypotension can be increased when Labetalol is combined with WIN 55212-2.Experimental
XamoterolThe therapeutic efficacy of Xamoterol can be decreased when used in combination with Labetalol.Experimental
XanthineThe risk or severity of adverse effects can be increased when Labetalol is combined with Xanthine.Experimental
XipamideLabetalol may increase the hypotensive activities of Xipamide.Experimental
XylazineThe therapeutic efficacy of Xylazine can be decreased when used in combination with Labetalol.Vet Approved
XylometazolineThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Labetalol.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Labetalol.Approved, Investigational, Vet Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Labetalol.Approved, Investigational
ZiconotideThe risk or severity of hypotension can be increased when Labetalol is combined with Ziconotide.Approved
ZimelidineThe serum concentration of Labetalol can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Ziprasidone.Approved
ZofenoprilLabetalol may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracZomepirac may decrease the antihypertensive activities of Labetalol.Withdrawn
ZonisamideThe risk or severity of hypotension can be increased when Labetalol is combined with Zonisamide.Approved, Investigational
ZuclopenthixolLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take without regard to meals.

References

Synthesis Reference

U.S. Patent 4,012,444.

General References
Not Available
External Links
Human Metabolome Database
HMDB0014736
KEGG Compound
C07063
PubChem Compound
3869
PubChem Substance
46505511
ChemSpider
3734
BindingDB
25758
ChEBI
6343
ChEMBL
CHEMBL429
Therapeutic Targets Database
DAP000038
PharmGKB
PA164743150
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Labetalol
ATC Codes
C07BG01 — Labetalol and thiazidesC07AG01 — LabetalolC07CG01 — Labetalol and other diuretics
AHFS Codes
  • 24:24.00 — Beta-adrenergic Blocking Agents
FDA label
Download (401 KB)
MSDS
Download (53.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedSupportive CareControlled Hypotension for Nasal Surgeries1
0RecruitingPreventionChronic Hypertension Complicating Pregnancy (Diagnosis) / Preeclampsia1
0RecruitingPreventionObesity, Morbid / Preeclampsia1
1, 2CompletedTreatmentCraniotomy / High Blood Pressure (Hypertension)1
1, 2WithdrawnTreatmentHigh Blood Pressure (Hypertension) / Pregnancy Toxemias / Proteinuria1
2CompletedTreatmentCocaine-Related Disorders1
2CompletedTreatmentIntracerebral Hemorrhage1
2CompletedTreatmentStroke, Acute1
2CompletedTreatmentTobacco Use Disorders1
2RecruitingTreatmentBloodpressure / Heart Rate1
2RecruitingTreatmentIntracerebral Hemorrhage1
2, 3RecruitingTreatmentSevere Pre-Eclampsia, Antepartum1
2, 3Unknown StatusTreatmentHydralazine Adverse Reaction / Pre-eclampsia Superimposed Pre-existing Hypertension / Pregnancy associated hypertension / Prophylaxis of preeclampsia1
2, 3WithdrawnPreventionChronic Hypertension / Gestational Hypertension / Preeclampsia / Pregnancy associated hypertension / Superimposed Preeclampsia1
3CompletedTreatmentPregnancy associated hypertension1
3Not Yet RecruitingTreatmentPostnatal Hypertension1
4CompletedTreatmentHypertensive Urgency1
4RecruitingPreventionHypertension, Pregnancy-Induced / Prophylaxis of preeclampsia1
4RecruitingPreventionSurgery, Laparoscopic1
4RecruitingTreatmentHigh Blood Pressure (Hypertension)1
4RecruitingTreatmentHypertension in Pregnancy / Preeclampsia2
Not AvailableCompletedTreatmentCVA (Cerebrovascular Accident) / Intracerebral Hemorrhage / Intracranial Hemorrhages1
Not AvailableCompletedTreatmentSevere Postpartum Hypertension1
Not AvailableUnknown StatusPreventionIntubation, Endotracheal / Patients Who Are Intubated for General Anesthesia1
Not AvailableWithdrawnTreatmentHigh Blood Pressure (Hypertension)1

Pharmacoeconomics

Manufacturers
  • Apothecon inc div bristol myers squibb
  • Bedford laboratories div ben venue laboratories inc
  • Claris lifesciences ltd
  • Hospira inc
  • Taylor pharmaceuticals
  • Sagent strides llc
  • Schering corp sub schering plough corp
  • Prometheus laboratories inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mutual pharmaceutical co inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
Packagers
  • Akorn Inc.
  • Amerisource Health Services Corp.
  • Apotex Inc.
  • Baxter International Inc.
  • Bedford Labs
  • Ben Venue Laboratories Inc.
  • Cardinal Health
  • Comprehensive Consultant Services Inc.
  • Diversified Healthcare Services Inc.
  • Eon Labs
  • Goldline Laboratories Inc.
  • Heartland Repack Services LLC
  • Hospira Inc.
  • Ivax Pharmaceuticals
  • Kaiser Foundation Hospital
  • Major Pharmaceuticals
  • Mckesson Corp.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Neuman Distributors Inc.
  • Novex Pharma
  • Nucare Pharmaceuticals Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Physicians Total Care Inc.
  • Prometheus Laboratories Inc.
  • Rebel Distributors Corp.
  • Sagent Pharmaceuticals
  • Sandhills Packaging Inc.
  • Southwood Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • UDL Laboratories
  • United Research Laboratories Inc.
  • Vangard Labs Inc.
  • Watson Pharmaceuticals
  • Wellspring Pharmaceutical
Dosage forms
FormRouteStrength
Injection, solutionIntravenous5 mg/mL
InjectionIntravenous5 mg/mL
TabletOral200 mg/1
TabletOral300 mg/1
Tablet, coatedOral100 mg/1
Tablet, coatedOral200 mg/1
Tablet, coatedOral300 mg/1
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral200 mg/1
Tablet, film coatedOral300 mg/1
LiquidIntravenous5 mg
SolutionIntravenous5 mg
TabletOral100 mg
TabletOral100 mg/1
TabletOral200 mg
Prices
Unit descriptionCostUnit
Labetalol Hydrochloride 5 mg/ml1.36USD ml
Trandate 300 mg tablet1.28USD tablet
Trandate 5 mg/ml vial1.25USD ml
Trandate 200 mg tablet1.08USD tablet
Labetalol hcl 300 mg tablet1.02USD tablet
Normodyne 200 mg tablet1.0USD tablet
Labetalol hcl 200 mg tablet0.76USD tablet
Trandate 100 mg tablet0.68USD tablet
Labetalol hcl 100 mg tablet0.53USD tablet
Trandate 200 mg Tablet0.47USD tablet
Trandate 100 mg Tablet0.27USD tablet
Labetalol hcl 5 mg/ml vial0.1USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)188 °CU.S. Patent 4,012,444.
water solubility117 mg/L (at 25 °C)MCFARLAND,JW ET AL. (2001)
logP3.09HANSCH,C ET AL. (1995)
Caco2 permeability-5.03ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.00578 mg/mLALOGPS
logP1.73ALOGPS
logP1.89ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)8.05ChemAxon
pKa (Strongest Basic)9.8ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area95.58 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity94.72 m3·mol-1ChemAxon
Polarizability36.83 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9943
Blood Brain Barrier-0.8313
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.7073
P-glycoprotein inhibitor INon-inhibitor0.8908
P-glycoprotein inhibitor IINon-inhibitor0.9269
Renal organic cation transporterNon-inhibitor0.8457
CYP450 2C9 substrateNon-substrate0.7448
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.6202
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorInhibitor0.8995
CYP450 3A4 inhibitorNon-inhibitor0.8256
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8383
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.9189
BiodegradationNot ready biodegradable0.945
Rat acute toxicity2.1174 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9501
hERG inhibition (predictor II)Non-inhibitor0.7398
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-03dl-7900000000-e18d52bcb93357c4a7e2
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-0319000000-cd3fa186952809ae3558
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03di-0519000000-0a8da4acfa8cd259fb3f
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03dl-4928000000-117458013dbd49aaf54b

Taxonomy

Description
This compound belongs to the class of organic compounds known as salicylamides. These are carboxamide derivatives of salicylic acid. Salicylic acid is the ortho-hydroxylated derivative of benzoic acid.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Salicylamides
Alternative Parents
Benzamides / Benzoyl derivatives / Aralkylamines / 1-hydroxy-2-unsubstituted benzenoids / Vinylogous acids / Secondary alcohols / Primary carboxylic acid amides / Amino acids and derivatives / 1,2-aminoalcohols / Dialkylamines
show 4 more
Substituents
Salicylamide / Benzamide / Benzoyl / 1-hydroxy-2-unsubstituted benzenoid / Phenol / Aralkylamine / Vinylogous acid / Amino acid or derivatives / 1,2-aminoalcohol / Secondary alcohol
show 16 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
benzamides, secondary amino compound (CHEBI:6343)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
References
  1. Riva E, Mennini T, Latini R: The alpha- and beta-adrenoceptor blocking activities of labetalol and its RR-SR (50:50) stereoisomers. Br J Pharmacol. 1991 Dec;104(4):823-8. [PubMed:1687367]
  2. Monopoli A, Bamonte F, Forlani A, Ongini E, Parravicini L: Effects of the R, R-isomer of labetalol, SCH 19927, in isolated tissues and in spontaneously hypertensive rats during a repeated treatment. Arch Int Pharmacodyn Ther. 1984 Dec;272(2):256-63. [PubMed:6151824]
  3. Sassard J, Zech PY, Pozet N, Cuisinaud G, Vincent M: [Comparative effects of an alpha 1 and beta 1-2 blocker (labetalol) and a beta-1 blocker (atenolol) in the hypertensive patient]. J Pharmacol. 1983;14 Suppl 2:121-9. [PubMed:6355664]
  4. Nakagawa Y, Takeda K, Sakurai H, Mitomi A, Imai S: [Antihypertensive effects of labetalol in three types of hypertensive models of rats (author's transl)]. Nihon Yakurigaku Zasshi. 1981 Apr;77(4):435-45. [PubMed:7286847]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  6. Pujos E, Cren-Olive C, Paisse O, Flament-Waton MM, Grenier-Loustalot MF: Comparison of the analysis of beta-blockers by different techniques. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Dec 1;877(31):4007-14. doi: 10.1016/j.jchromb.2009.10.014. Epub 2009 Oct 17. [PubMed:19879818]
  7. Rosendorff C: Beta-blocking agents with vasodilator activity. J Hypertens Suppl. 1993 Jun;11(4):S37-40. [PubMed:8104240]
  8. van Zwieten PA: An overview of the pharmacodynamic properties and therapeutic potential of combined alpha- and beta-adrenoceptor antagonists. Drugs. 1993 Apr;45(4):509-17. [PubMed:7684671]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
Gene Name
ADRB2
Uniprot ID
P07550
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
References
  1. Doggrell SA: The effects of labetalol and dilevalol on isolated cardiovascular preparations of the guinea-pig and rat. J Pharm Pharmacol. 1992 Dec;44(12):1001-6. [PubMed:1361547]
  2. Doggrell SA: Relaxant and beta 2-adrenoceptor blocking activities of labetalol, dilevalol, amosulalol and KF-4317 on the rat isolated aorta. J Pharm Pharmacol. 1988 Nov;40(11):812-5. [PubMed:2907566]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  4. Sassard J, Zech PY, Pozet N, Cuisinaud G, Vincent M: [Comparative effects of an alpha 1 and beta 1-2 blocker (labetalol) and a beta-1 blocker (atenolol) in the hypertensive patient]. J Pharmacol. 1983;14 Suppl 2:121-9. [PubMed:6355664]
  5. Pujos E, Cren-Olive C, Paisse O, Flament-Waton MM, Grenier-Loustalot MF: Comparison of the analysis of beta-blockers by different techniques. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Dec 1;877(31):4007-14. doi: 10.1016/j.jchromb.2009.10.014. Epub 2009 Oct 17. [PubMed:19879818]
  6. Rosendorff C: Beta-blocking agents with vasodilator activity. J Hypertens Suppl. 1993 Jun;11(4):S37-40. [PubMed:8104240]
  7. van Zwieten PA: An overview of the pharmacodynamic properties and therapeutic potential of combined alpha- and beta-adrenoceptor antagonists. Drugs. 1993 Apr;45(4):509-17. [PubMed:7684671]
Kind
Protein group
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...

Components:
References
  1. Bernstein JS, Ebert TJ, Stowe DF, Schmeling WT, Nelson MA, Woods MP: Partial attenuation of hemodynamic responses to rapid sequence induction and intubation with labetalol. J Clin Anesth. 1989;1(6):444-51. [PubMed:2696507]
  2. Nakamura T, Maruyama K, Ohnuki T, Hattori K, Watanabe K, Nagatomo T: Tamsulosin: assessment of affinityof (3)H-P razosin binding to two alpha-1- adrenoceptor subtypes in the canine aorta. Pharmacology. 1999 Nov;59(5):234-8. [PubMed:10529655]
  3. Sassard J, Zech PY, Pozet N, Cuisinaud G, Vincent M: [Comparative effects of an alpha 1 and beta 1-2 blocker (labetalol) and a beta-1 blocker (atenolol) in the hypertensive patient]. J Pharmacol. 1983;14 Suppl 2:121-9. [PubMed:6355664]
  4. Pedersen ME, Cockcroft JR: The vasodilatory beta-blockers. Curr Hypertens Rep. 2007 Aug;9(4):269-77. [PubMed:17686376]
  5. Shiraishi K, Moriya M, Miyake N, Takayanagi I: Alpha 1-adrenoceptor blocking activities of bevantolol hydrochloride(NC-1400) and labetalol in rat isolated thoracic aorta--do they distinguish between subtypes? Gen Pharmacol. 1992 Sep;23(5):843-5. [PubMed:1358746]
  6. Rosendorff C: Beta-blocking agents with vasodilator activity. J Hypertens Suppl. 1993 Jun;11(4):S37-40. [PubMed:8104240]
  7. van Zwieten PA: An overview of the pharmacodynamic properties and therapeutic potential of combined alpha- and beta-adrenoceptor antagonists. Drugs. 1993 Apr;45(4):509-17. [PubMed:7684671]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Flockhart Table - Indiana University [Link]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:42